Villanueva, Jessie <br/><br/>
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.  [electronic resource] 

 -  Cancer cell  Dec 2010 
 - 683-95 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1878-3686 
<br/><br/><label>Standard No.: </label>10.1016/j.ccr.2010.11.023  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Cell Line, Tumor<br/>Drug Resistance, Neoplasm<br/>Humans<br/>MAP Kinase Signaling System<br/>Melanoma--drug therapy<br/>Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors<br/>Phosphatidylinositol 3-Kinases--physiology<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Phosphorylation<br/>Proto-Oncogene Proteins B-raf--antagonists & inhibitors<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Receptor, IGF Type 1--antagonists & inhibitors<br/>raf Kinases--physiology